Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

IBUPROFEN

8 general benefit · 3 not a benefit

Other products in the same Health Canada class (M01AE) — coverage varies; not interchangeable

  • Flurbiprofen (Ansaid): general benefit, Not a benefit
  • Ketoprofen (Ketoprofen): general benefit, Not a benefit
  • Naproxen (Naprosyn E): general benefit, Not a benefit
  • Tiaprofenic acid (Surgam): general benefit, Not a benefit
  • Esomeprazole + naproxen (Vimovo): not a benefit
  • Naproxen (Teva-Naproxen Sodium): not a benefit

12 more in the class list below

Apo-Ibuprofen · DIN 00441643 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ibuprofen · DIN 00441643 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-11-05 · brand APO-IBUPROFEN · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 200 MG · company Apotex inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Apo-Ibuprofen: Formulary list price $0.0309/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0309 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10294 · Verify on the e-Formulary ↗ (DIN 00441643)

Source record
DIN 00441643: Apo-Ibuprofen Raw flags: sec3=Y Item: 280804019; group id 382; item number 0911; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.0309; ministry $0.0309 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00441643 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10294 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Ibuprofen · DIN 02257912 · $0.0309 Motrin · DIN 00252409 · not recorded
Shortage status: resolved shortage (ended 2024-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00441643
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ibuprofen · DIN 02257912 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ibuprofen · DIN 02257912 Manufacturer: Jamp Pharma Corporation; listing date 2023-02-28 Health Canada: Marketed since 2022-12-16 · brand IBUPROFEN 200 MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 200 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ibuprofen: Formulary list price $0.0309/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0309 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74314 · Verify on the e-Formulary ↗ (DIN 02257912)

Source record
DIN 02257912: Ibuprofen Raw flags: sec3=Y Item: 280804019; group id 382; item number 0911; lccId None; manufacturer id JPC Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $0.0309; ministry $0.0309 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02257912 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74314 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00441643 · $0.0309 Motrin · DIN 00252409 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02257912
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ibuprofen · DIN 00441651 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ibuprofen · DIN 00441651 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2021-01-06 · brand APO-IBUPROFEN · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 300 MG · company Apotex inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Apo-Ibuprofen: Formulary list price $0.1377/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1377 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5433 · Verify on the e-Formulary ↗ (DIN 00441651)

Source record
DIN 00441651: Apo-Ibuprofen Raw flags: sec3=Y Item: 280804020; group id 382; item number 0912; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $0.1377; ministry $0.1377 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00441651 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5433 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Motrin · DIN 00327794 · not recorded
Shortage status: resolved shortage (ended 2021-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00441651
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ibuprofen · DIN 00506052 · 400mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Ibuprofen · DIN 00506052 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-11-05 · brand APO-IBUPROFEN · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 400 MG · company Apotex inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Apo-Ibuprofen: Formulary list price $0.0468/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0468 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5432 · Verify on the e-Formulary ↗ (DIN 00506052)

Source record
DIN 00506052: Apo-Ibuprofen Raw flags: sec3=Y Item: 280804021; group id 382; item number 0913; lccId None; manufacturer id APX Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.0468; ministry $0.0468 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00506052 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5432 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Ibuprofen · DIN 02317338 · $0.0468 Motrin · DIN 00364142 · $0.0468
Shortage status: resolved shortage (ended 2024-04-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00506052
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ibuprofen · DIN 02317338 · 400mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ibuprofen · DIN 02317338 Manufacturer: Jamp Pharma Corporation; listing date 2023-02-28 Health Canada: Marketed since 2022-12-16 · brand IBUPROFEN 400 MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 400 MG · company Jamp pharma corporation · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ibuprofen: Formulary list price $0.0468/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0468 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80286 · Verify on the e-Formulary ↗ (DIN 02317338)

Source record
DIN 02317338: Ibuprofen Raw flags: sec3=Y Item: 280804021; group id 382; item number 0913; lccId None; manufacturer id JPC Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.0468; ministry $0.0468 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02317338 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80286 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00506052 · $0.0468 Motrin · DIN 00364142 · $0.0468
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02317338
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ibuprofen · DIN 00585114 · 600mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ibuprofen · DIN 00585114 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2020-12-28 · brand APO-IBUPROFEN TAB 600MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 600 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ibuprofen: Formulary list price $0.1313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5917 · Verify on the e-Formulary ↗ (DIN 00585114)

Source record
DIN 00585114: Apo-Ibuprofen Raw flags: sec3=Y Item: 280804022; group id 382; item number 0914; lccId None; manufacturer id APX Source form: Tab; strength: 600mg Recorded listing: General benefit Source prices (unrounded): $0.1313; ministry $0.1313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00585114 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5917 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Motrin · DIN 00484911 · not recorded Novo-Profen · DIN 00629359 · $0.1313
Shortage status: shortage reported ended 2026-07-02 (report last updated 2026-07-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00585114
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Motrin · PIN 00252409 · 200mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Motrin · DIN 00252409 Manufacturer: The Upjohn Company of Canada; listing date 2006-06-15 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Motrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00252409)

Source record
DIN 00252409: Motrin Raw flags: notABenefit=Y, sec3=Y Item: 280804019; group id 382; item number 0911; lccId None; manufacturer id UPJ Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00252409 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00441643 · $0.0309 Ibuprofen · DIN 02257912 · $0.0309
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00252409
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Motrin · DIN 00364142 · 400mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.Discontinued 2002-05-14 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Motrin · DIN 00364142 Manufacturer: The Upjohn Company of Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-05-14 · brand MOTRIN TABLETS 400MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 400 MG · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Ministry pays: $0.0468 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2903 · Verify on the e-Formulary ↗ (DIN 00364142)

Source record
DIN 00364142: Motrin Raw flags: sec3=Y Item: 280804021; group id 382; item number 0913; lccId None; manufacturer id UPJ Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.1871; ministry $0.0468 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00364142 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2903 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00506052 · $0.0468 Ibuprofen · DIN 02317338 · $0.0468
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00364142
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-05-14 — choose a marketed DIN from the same-category list.

Novo-Profen · DIN 00629359 · 600mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.Discontinued 2025-07-23 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novo-Profen · DIN 00629359 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2025-07-23 · brand TEVA-PROFEN · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 600 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Novo-Profen: Formulary list price $0.1313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6323 · Verify on the e-Formulary ↗ (DIN 00629359)

Source record
DIN 00629359: Novo-Profen Raw flags: sec3=Y Item: 280804022; group id 382; item number 0914; lccId None; manufacturer id NOP Source form: Tab; strength: 600mg Recorded listing: General benefit Source prices (unrounded): $0.1313; ministry $0.1313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00629359 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6323 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00585114 · $0.1313 Motrin · DIN 00484911 · not recorded
Shortage status: discontinued (2019-05-01, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00629359
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-23 — choose a marketed DIN from the same-category list.

Motrin · DIN 00327794 · 300mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-15 — choose a marketed DIN from the same-category list.Discontinued 2002-05-15 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-05-15 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-05-15 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Motrin · DIN 00327794 Manufacturer: The Upjohn Company of Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-05-15 · brand MOTRIN TABLETS 300MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 300 MG · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Motrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2225 · Verify on the e-Formulary ↗ (DIN 00327794)

Source record
DIN 00327794: Motrin Raw flags: notABenefit=Y, sec3=Y Item: 280804020; group id 382; item number 0912; lccId None; manufacturer id UPJ Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00327794 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2225 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00441651 · $0.1377
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00327794
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-05-15 — choose a marketed DIN from the same-category list.

Motrin · DIN 00484911 · 600mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-07-22 — choose a marketed DIN from the same-category list.Discontinued 2004-07-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-07-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2004-07-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Motrin · DIN 00484911 Manufacturer: The Upjohn Company of Canada; listing date 1996-10-01 Health Canada: Cancelled post market since 2004-07-22 · brand MOTRIN TABLETS 600MG · ATC M01AE01 IBUPROFEN · form Tablet · route Oral · ingredients IBUPROFEN 600 MG · company Mcneil consumer healthcare division of johnson & johnson inc · schedule Prescription
Check this DIN again · Health Canada product record

Motrin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3737 · Verify on the e-Formulary ↗ (DIN 00484911)

Source record
DIN 00484911: Motrin Raw flags: notABenefit=Y, sec3=Y Item: 280804022; group id 382; item number 0914; lccId None; manufacturer id UPJ Source form: Tab; strength: 600mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00484911 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3737 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ibuprofen · DIN 00585114 · $0.1313 Novo-Profen · DIN 00629359 · $0.1313
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00484911
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2004-07-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab

NAPROXEN & ESOMEPRAZOLE MAGNESIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 375mg & 20mg, 500mg & 20mg · MR Tab

NAPROXEN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 275mg, 550mg · Tab

OXAPROZIN.

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 600mg · Tab

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-IBUPROFEN and APO-IBUPROFEN CAPLET (ibuprofen tablets) are indicated for fast and effective relief of: • headache pain (including mild to moderate migraine and tension headache) • menstrual pain • toothache (dental pain) • pain from inflammation associated with conditions including: ▪ arthritis ▪ physical or athletic overexertion, (e.g., sprains or strains) • minor aches and pains in muscles, bones and joints • backache • the aches and pain due to the common cold and flu • reduction of fever 1.1 Pediatrics Pediatrics (<12 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggest that use in the geriatric population is associated with differences in safety or effectiveness and a brief discussion can be found in the appropriate sections (e.g., Warnings and Precautions). https://pdf.hres.ca/dpd_pm/00078209.PDF PM date: JAN 07, 2025 Source product: APO-IBUPROFEN; DIN 00441643; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Ibuprofen · DIN 00585114 Shortage status: shortage reported ended 2026-07-02 (report last updated 2026-07-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00585114

Check this DIN again

Novo-Profen · DIN 00629359 Shortage status: discontinued (2019-05-01, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00629359

Check this DIN again

Other review policies

For Motrin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026